7FIN image
Entry Detail
PDB ID:
7FIN
EMDB ID:
Title:
Cryo-EM structure of the GIPR/GLP-1R/GCGR triagonist peptide 20-bound human GIPR-Gs complex
Biological Source:
PDB Version:
Deposition Date:
2021-07-31
Release Date:
2022-02-23
Method Details:
Experimental Method:
Resolution:
3.10 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(s) subunit alpha isoforms short
Mutations:8
Chain IDs:C (auth: A)
Chain Length:394
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Chain IDs:D (auth: B)
Chain Length:371
Number of Molecules:1
Biological Source:Rattus norvegicus
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Chain IDs:E (auth: G)
Chain Length:71
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:Nanobody-35
Chain IDs:F (auth: N)
Chain Length:140
Number of Molecules:1
Biological Source:synthetic construct
Polymer Type:polypeptide(L)
Description:Peptide 20
Chain IDs:B (auth: P)
Chain Length:39
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Gastric inhibitory polypeptide receptor,human glucose-dependent insulinotropic polypeptide receptor
Mutations:T345F
Chain IDs:A (auth: R)
Chain Length:573
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
Nat Commun 13 1057 1057 (2022)
PMID: 35217653 DOI: 10.1038/s41467-022-28683-0

Abstact

Glucose homeostasis, regulated by glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) is critical to human health. Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity. To elucidate the molecular mechanisms by which tirzepatide, a GIPR/GLP-1R dual agonist, and peptide 20, a GIPR/GLP-1R/GCGR triagonist, manifest their multiplexed pharmacological actions over monoagonists such as semaglutide, we determine cryo-electron microscopy structures of tirzepatide-bound GIPR and GLP-1R as well as peptide 20-bound GIPR, GLP-1R and GCGR. The structures reveal both common and unique features for the dual and triple agonism by illustrating key interactions of clinical relevance at the near-atomic level. Retention of glucagon function is required to achieve such an advantage over GLP-1 monotherapy. Our findings provide valuable insights into the structural basis of functional versatility of tirzepatide and peptide 20.

Legend

Protein

Chemical

Disease

Primary Citation of related structures